Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery there, and her son is currently a thoracic surgeon at the hospital.
But Glimcher, the CEO of the neighboring Dana-Farber Cancer Institute, has no qualms about the contentious decision to sever a 30-year partnership with Massachusetts General’s parent organization.
The move will turn Dana-Farber and Mass General Brigham into competitors for cancer patients in the Boston area, and at the annual STAT Summit in Boston Wednesday, Glimcher asserted that it is actually a good change for patients, one that will lead to lower costs and help the region address the rising rates of cancer in an aging population.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect